| pubmed-article:19086780 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19086780 | lifeskim:mentions | umls-concept:C0003062 | lld:lifeskim |
| pubmed-article:19086780 | lifeskim:mentions | umls-concept:C0079925 | lld:lifeskim |
| pubmed-article:19086780 | lifeskim:mentions | umls-concept:C0184511 | lld:lifeskim |
| pubmed-article:19086780 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:19086780 | lifeskim:mentions | umls-concept:C0205217 | lld:lifeskim |
| pubmed-article:19086780 | lifeskim:mentions | umls-concept:C0443288 | lld:lifeskim |
| pubmed-article:19086780 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:19086780 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:19086780 | lifeskim:mentions | umls-concept:C1579410 | lld:lifeskim |
| pubmed-article:19086780 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:19086780 | pubmed:dateCreated | 2009-1-2 | lld:pubmed |
| pubmed-article:19086780 | pubmed:abstractText | The potency of second generation antisense oligonucleotides (ASOs) in animals was increased 3- to 5 -fold (ED(50) approximately 2-5 mg/kg) without producing hepatotoxicity, by reducing ASO length (20-mer to 14-mer) and by employing novel nucleoside modifications that combine structural elements of 2'-O-methoxyethyl residues and locked nucleic acid. The ability to achieve this level of potency without any formulation agents is remarkable and likely to have a significant impact on the future design of ASOs as therapeutic agents. | lld:pubmed |
| pubmed-article:19086780 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19086780 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19086780 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19086780 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19086780 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19086780 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19086780 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19086780 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19086780 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:19086780 | pubmed:issn | 1520-4804 | lld:pubmed |
| pubmed-article:19086780 | pubmed:author | pubmed-author:PrakashThazha... | lld:pubmed |
| pubmed-article:19086780 | pubmed:author | pubmed-author:VasquezGuille... | lld:pubmed |
| pubmed-article:19086780 | pubmed:author | pubmed-author:WitchellDonna... | lld:pubmed |
| pubmed-article:19086780 | pubmed:author | pubmed-author:SwayzeEric... | lld:pubmed |
| pubmed-article:19086780 | pubmed:author | pubmed-author:WancewiczEdwa... | lld:pubmed |
| pubmed-article:19086780 | pubmed:author | pubmed-author:SiwkowskiAndr... | lld:pubmed |
| pubmed-article:19086780 | pubmed:author | pubmed-author:AllersonCharl... | lld:pubmed |
| pubmed-article:19086780 | pubmed:author | pubmed-author:SethPunit PPP | lld:pubmed |
| pubmed-article:19086780 | pubmed:author | pubmed-author:LeeSamS | lld:pubmed |
| pubmed-article:19086780 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19086780 | pubmed:day | 8 | lld:pubmed |
| pubmed-article:19086780 | pubmed:volume | 52 | lld:pubmed |
| pubmed-article:19086780 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19086780 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19086780 | pubmed:pagination | 10-3 | lld:pubmed |
| pubmed-article:19086780 | pubmed:meshHeading | pubmed-meshheading:19086780... | lld:pubmed |
| pubmed-article:19086780 | pubmed:meshHeading | pubmed-meshheading:19086780... | lld:pubmed |
| pubmed-article:19086780 | pubmed:meshHeading | pubmed-meshheading:19086780... | lld:pubmed |
| pubmed-article:19086780 | pubmed:meshHeading | pubmed-meshheading:19086780... | lld:pubmed |
| pubmed-article:19086780 | pubmed:meshHeading | pubmed-meshheading:19086780... | lld:pubmed |
| pubmed-article:19086780 | pubmed:meshHeading | pubmed-meshheading:19086780... | lld:pubmed |
| pubmed-article:19086780 | pubmed:meshHeading | pubmed-meshheading:19086780... | lld:pubmed |
| pubmed-article:19086780 | pubmed:meshHeading | pubmed-meshheading:19086780... | lld:pubmed |
| pubmed-article:19086780 | pubmed:meshHeading | pubmed-meshheading:19086780... | lld:pubmed |
| pubmed-article:19086780 | pubmed:meshHeading | pubmed-meshheading:19086780... | lld:pubmed |
| pubmed-article:19086780 | pubmed:meshHeading | pubmed-meshheading:19086780... | lld:pubmed |
| pubmed-article:19086780 | pubmed:meshHeading | pubmed-meshheading:19086780... | lld:pubmed |
| pubmed-article:19086780 | pubmed:meshHeading | pubmed-meshheading:19086780... | lld:pubmed |
| pubmed-article:19086780 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19086780 | pubmed:articleTitle | Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. | lld:pubmed |
| pubmed-article:19086780 | pubmed:affiliation | Isis Pharmaceuticals, 1891 Rutherford Road, Carlsbad, California 92008, USA. pseth@isisph.com | lld:pubmed |
| pubmed-article:19086780 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:19086780 | lld:chembl |
